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While sarcopenia has been associated with decreased overall survival in diffuse large B-cell 
(DLBCL) patients, the impact of sarcopenia on treatment tolerance has not been well-
studied. We evaluated the association of sarcopenia with febrile neutropenia 
hospitalization, treatment-related mortality, and ability to complete standard number of 
cycles in a retrospective cohort of United States veterans diagnosed with DLBCL between 
1998 and 2008 and treated with cyclophosphamide, doxorubicin, vincristine, and 
prednisone, with or without rituximab. Baseline body composition parameters were 
evaluated using computed tomography analysis. In total, 522 patients were included in the 
study, of whom 245 (47%) had baseline sarcopenia. After controlling for other variables, 
baseline sarcopenia was independently associated with increased risk of febrile neutropenia 
hospitalization (adjusted Odds Ratio (aOR) 1.64, 95% Confidence Interval (CI) 1.01 to 
2.65) and inability to complete standard number of treatment cycles (aOR 1.49, 95% CI 
1.02 to 2.16) compared with no baseline sarcopenia. There was a non-statistically 
significant trend towards higher treatment-related mortality in sarcopenic patients than non-
sarcopenic patients (aOR 1.77, 95% CI 0.92 to 3.41). Sarcopenia is associated with 
increased risk of treatment intolerance and may be useful in guiding treatment planning and 
supportive care measures.  
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Diffuse large B-cell lymphoma (DLBCL) is the most common non-Hodgkin lymphoma 
(NHL), accounting for 30% of all NHL cases [1,2]. Sarcopenia, or the presence of low 
muscle mass, has been associated with decreased overall survival in patients with DLBCL 
[3–5]. However, the impact of sarcopenia on other outcomes, including treatment toxicity, 
treatment-related mortality, and ability to complete standard therapy, has not been well-
studied in the DLBCL population.  
Understanding the relationship of low muscle mass with treatment tolerance may be 
useful for guiding individual treatment decisions and supportive care measures. Treatment 
with R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone) is 
the current standard of care, front-line therapy for DLBCL [6]. In patients receiving CHOP-
based therapy, maintaining dose intensity >70-90% has been associated with improved 
overall survival [7–9]. However, the benefits of standard, full-dose therapy must be 
weighed against the risks of treatment-related complications. There is evidence from solid 
tumor cancers that body composition parameters could be used to assess risk for 
chemotherapy toxicity. For example, sarcopenia has been associated with increased dose-
limiting toxicities in patients undergoing treatment for colon, breast, and renal cell cancer 
[10–12]. 
In this study, we evaluated a cohort of United States veterans with DLBCL diagnosed 
within the United States Veterans Health Administration (VHA) system and treated with 
cyclophosphamide, doxorubicin, vincristine, and prednisone, with or without rituximab 
(CHOP +/- R). The primary objective of this study is to evaluate the association of 
sarcopenia with hospitalizations for febrile neutropenia, one of the major dose-limiting 
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toxicities associated with CHOP-based therapy. Secondary outcomes of interest include 
treatment-related mortality and completion of standard number of treatment cycles. 
Methods 
Study Cohort 
A retrospective cohort of patients with a new diagnosis of DLBCL between October 1, 
1998 and September 30, 2008 was assembled from the Veteran’s Health Administration 
Central Cancer Registry (VACCR) based on the InterLymph classification system 
(International Classification of Diseases (ICD) -O3 codes 9680/3 and 9684/3 for DLBCL) 
[13]. Data were obtained from all 21 VHA regions throughout the United States. Patients 
were excluded for the following reasons: missing vital status, central nervous system 
involvement, tested positive for human immunodeficiency virus, primary cutaneous 
DLBCL, inadequate histologic confirmation, treatment with regimens other than CHOP +/- 
R, no treatment, treatment outside of the VHA, or no baseline computed tomography (CT) 
scan. The study was approved by the Veterans Affairs St. Louis Health Care System and 
Washington University institutional review boards prior to cohort assembly. 
Clinical Data Collection 
Data on histologic diagnosis, date of birth, date of diagnosis, race, sex, disease stage, and 
the presence of systemic B-symptoms (fever 100.4°F, weight loss >10% of body weight in 
6 months, and night sweats) were provided by VACCR. Patient records were also linked to 
additional VHA administrative datasets to obtain vital sign data including height and 
weight, ICD-9 codes for comorbid conditions, and date of death.  Focused data abstraction 
was performed using the VHA Compensation and Pension Records Interchange software 
system to collect data on lactate dehydrogenase (LDH) levels; chemotherapy drugs, doses, 
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and dates of administration; myeloid growth factor doses and dates of administration; and 
hospitalization dates and admission diagnoses. CT scans were accessed through the VistA 
Imaging System’s Advanced Web Image Viewer (AWIV). 
Outcome Definitions 
The primary outcome of interest was hospitalization for febrile neutropenia, defined as any 
hospitalization with febrile neutropenia as the admission diagnosis.  
Secondary outcomes of interest included treatment-related mortality and completion 
of standard number of chemotherapy cycles. Treatment-related mortality was defined as 
death <=30 days after last chemotherapy treatment. Standard number of cycles was defined 
as a minimum of 3 treatment cycles in patients with stage I or II disease who received 
radiotherapy and a minimum of 6 treatment cycles in all other patients [14].   
Study Independent Variables and Definitions 
The Romano adaptation of the Charlson co-morbidity index was calculated for patients 
included in the study cohort using ICD-9 codes for co-morbid conditions present at the time 
of diagnosis [15]. Age at diagnosis was dichotomized to ≥ 65 years of age and <65 years of 
age for analyses involving febrile neutropenia risk in concordance with current guidelines 
for prophylactic growth factor use [16]; or to >60 years of age and ≤60 years of age in 
analyses involving treatment-related mortality or completion of standard therapy in 
concordance with the International Prognostic Index for aggressive non-Hodgkin’s 
lymphoma [17]. Age was used as a continuous variable in other analyses. LDH was 
dichotomized as elevated or not elevated at time of diagnosis based on local reference 
ranges. 
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BMI was calculated as weight measured in kilograms divided by the square of 
height measured in meters (kg/m
2
) and was categorized in accordance with World Health 
Organization guidelines [18]. Body Surface Area (BSA) was calculated according to the 
DuBois formula [19] using weight measured within one month of treatment initiation and 
consistently recorded height data. Early granulocyte-colony stimulating factor (G-CSF) use 
was defined as any administration of G-CSF during the first 5 days of the first cycle of 
chemotherapy. 
Agent-specific relative dose intensity was defined as the ratio of dose actually 
delivered over time to the standard dose intensity [20]. The standard doxorubicin and 
cyclophosphamide dose was 50 mg/m
2
 and 750 mg/m
2
, respectively, administered at 
twenty-one day intervals. The average relative dose intensity (ARDI) for each patient was 
obtained by averaging the agent-specific relative dose intensities of doxorubicin and 
cyclophosphamide. Consistent with previous literature, ARDI of ≥ 85% was considered full 
dose intensity, while < 85% was considered reduced dose intensity [21]. 
Body composition analysis was performed on computed tomography (CT) scans 
obtained within three months prior to treatment initiation. Analysis was performed by a 
single trained reviewer (DYX) who was blinded to the primary outcome. An axial image at 
the third lumbar vertebral level (L3) was identified [22] and this image was thresholded 
based on standard Hounsfield unit (HU) ranges for skeletal muscle (-29 to +150). The 
thresholded images were then copied into the National Institute of Health’s ImageJ 
Program, and skeletal muscle area was computed for each image in cm
2
 (Figure 1). 
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in women, based on previously published values [23]. No other 
threshold values were tested. 
Statistical Analyses 
Chi-square, Mann-Whitney U, and student’s t-test were used for analyses, where 
appropriate. Univariate logistic regression explored factors associated with febrile 
neutropenia hospitalization, treatment-related mortality, and inability to complete standard 
number of treatment cycles. Variables with p-value <0.05 on univariate analysis were then 
entered simultaneously into a multivariable logistic regression model. A two-tailed α 
significance level of 0.05 was considered statistically significant.  All statistical analyses 
were performed using IBM SPSS version 20. 
Results 
Patient demographics and clinical characteristics 
Of the 3,227 patients with DLBCL initially identified, 1837 patients remained after 
applying exclusion criteria (Figure 2). Of these patients, 1315 did not have baseline CT 
scans uploaded to the national database, leaving a final cohort of 522 patients with baseline 
body composition information. Baseline characteristics of those who did and did not have 
baseline CT scans were similar (Supplementary Table S1). 
 Patient characteristics by sarcopenia status are summarized in Table I. Forty-seven 
percent of patients were classified as sarcopenic.  Compared to non-sarcopenic patients, 
sarcopenic patients were more likely to be older (mean age 68.1 years versus 61.2 years, 
p<0.001), white (93.1% versus 83.8%, p=0.005), have a higher comorbidity index (mean 
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score 2.3 versus 1.9, p=0.018), have B-symptoms (60.0% versus 52.7%, p=0.004), and 
have a lower mean BMI (24.6 versus 29.2, p<0.001). 
Hospitalizations for febrile neutropenia 
There were a total of 435 unplanned hospitalizations across all treatment cycles, and of 
these 150 had an admission diagnosis of febrile neutropenia. Overall, 116 patients (22.2%) 
had at least one hospitalization for febrile neutropenia. In the entire cohort, 28.2% of 
sarcopenic patients had at least one hospitalization for febrile neutropenia, compared to 
17.0% of non-sarcopenic patients (p=0.002). In the R-CHOP subgroup, 26.9% of 
sarcopenic patients had at least one hospitalization for febrile neutropenia, compared to 
15.9% of non-sarcopenic patients (p=0.008). 
In addition to baseline sarcopenia, other factors associated with febrile neutropenia 
hospitalization on univariate analysis included: age ≥ 65 years, comorbidity score, stage 
III/IV, presence of B-symptoms, first-cycle ARDI ≥ 85%, and underweight BMI (Table II). 
Variables with a p-value <0.05 identified by univariate analysis were further tested in a 
multiple logistic regression model (n=522). In the multivariable model, baseline sarcopenia 
was an independent predictor of febrile neutropenia (Odds Ratio (OR) 1.64, 95% 
Confidence Interval (CI) 1.01 to 2.65). Other factors independently associated with higher 
febrile neutropenia risk included comorbidity score (OR 1.23, 95% CI 1.09 to 1.39), stage 
III/IV (OR 1.66, 95% CI 1.04 to 2.65), and first-cycle ARDI ≥ 85% (OR 3.21, 95% CI 1.40 
to 7.40). 
Treatment-related mortality 
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In the entire cohort, 44 patients (8.4%) died within 30 days of receiving chemotherapy. The 
majority of deaths occurred during the first cycle of chemotherapy, with 21 occurring in the 
first cycle, 8 in the second cycle, 4 in the third, fourth, and sixth cycles, and 3 in the fifth 
cycle. In the entire cohort, treatment-related mortality occurred in 11.4% of sarcopenic 
patients, compared to 5.8% of non-sarcopenic patients (p=0.020). In the R-CHOP 
subgroup, treatment-related mortality occurred in 11.2% of sarcopenic patients, compared 
to 5.4% of non-sarcopenic patients (p=0.029). 
In addition to baseline sarcopenia, age > 60 years was also associated with 
treatment-related mortality on univariate analysis (Supplementary Table S2). After 
adjusting for age, there was a non-statistically significant trend towards increased 
treatment-related mortality in sarcopenic patients (OR 1.77, 95% CI 0.92 to 3.41) compared 
to non-sarcopenic patients.  
Completion of standard therapy 
There was no difference in ARDI across all delivered cycles between sarcopenic and non-
sarcopenic patients, with 61% of sarcopenic patients receiving ARDI ≥ 85% across all 
delivered cycles compared to 60% of nonsarcopenic patients (p=0.762). However, 
sarcopenic patients were less likely to complete the standard number of cycles, with only 
59.2% of sarcopenic patients completing the standard number of treatment cycles compared 
to 70.4% of non-sarcopenic patients (p=0.007). In the R-CHOP subgroup, 60.4% of 
sarcopenic patients versus 70.3% of non-sarcopenic patients completed standard treatment 
(p=0.028). In the CHOP subgroup, 50.0% of sarcopenic patients versus 71.1% of non-
sarcopenic patients completed standard treatment (p=0.08). 
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In addition to baseline sarcopenia, other factors associated with inability to 
complete the standard number of treatment cycles included age > 60 years and higher 
comorbidity score (Supplementary Table S3). After controlling for age and comorbidity 
score, baseline sarcopenia was an independent predictor of inability to complete standard 
number of treatment cycles (OR 1.49, 95% CI 1.02 to 2.16). 
Discussion 
 This study evaluated the association of sarcopenia with treatment tolerability and 
feasibility in a largely white male cohort of patients with DLBCL. Compared with non-
sarcopenic patients, sarcopenic patients had increased risk of febrile neutropenia 
hospitalization and a trend towards increased risk of treatment-related mortality after 
controlling for other variables. Sarcopenic patients were also less likely to complete the 
standard number of treatment cycles compared to non-sarcopenic patients. 
These results are consistent with previous literature evaluating sarcopenia in 
patients with hematologic malignancies. In a cohort of 82 elderly patients with DLBCL, 
Lanic et al. found that 60% of sarcopenic patients with DLBCL completed therapy 
compared to 84% of non-sarcopenic patients [3]. Similarly, in a cohort of 187 Korean 
patients with DLBCL, Go et al. reported that both treatment-related mortality (21.7% vs. 
5.0%) and early treatment discontinuation (32.6% vs 14.9%) were higher in sarcopenic 
patients compared to non-sarcopenic patients. Finally, Caram et al. found that sarcopenia, 
as measured by psoas muscle index, was associated with higher complication rates and 
longer hospital stays in men undergoing autologous transplant for non-Hodgkin or Hodgkin 
lymphoma [24].  
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We found that sarcopenia was an independent predictor of febrile neutropenia 
hospitalization. Consistent with previously published studies, other variables associated 
with febrile neutropenia hospitalization in this study included higher comorbidity index, 
advanced stage, and first-cycle ARDI ≥85% [25]. Lower BMI was also associated with 
increased risk of febrile neutropenia [26], but the association was no longer significant after 
controlling for sarcopenia. We observed a trend towards increased risk for febrile 
neutropenia hospitalization in patients with early G-CSF use compared with those without 
early G-CSF use. This is in contrast to previously published randomized controlled trials 
which demonstrate protective effects with primary G-CSF prophylaxis [27]. This is likely 
explained by confounding by indication, as patients at higher risk for febrile neutropenia 
may have been more likely to be prescribed primary G-CSF prophylaxis.  
We observed a trend towards increased risk of treatment-related mortality in 
sarcopenic patients compared to non-sarcopenic patients, and consistent with previous 
studies, observed that the majority of treatment-related deaths occurred in the first cycle 
[28]. While no study has specifically evaluated sarcopenia as a predictor of early death, 
Peyrade et al. found that low albumin level was associated with poorer overall survival in a 
cohort of elderly patients with DLBCL, and Soubeyran et al. found that the Mini 
Nutritional Assessment (MNA) and the Timed Get Up and Go (GUG) were associated with 
early death in a cohort of elderly cancer patients [28,29]. Sarcopenia has been associated 
with decreased MNA scores in previous studies and may reflect both poor nutritional status 
and decreased functional mobility [30]. Taken together, these results lend evidence that 
nutritional parameters, along with muscle mass and strength, may be important for 
predicting treatment-related mortality. 
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The mechanism for increased chemotherapy toxicity in sarcopenic patients has not 
been well-studied. One potential hypothesis is that altered body composition may affect the 
distribution, metabolism, and clearance of chemotherapy drugs [31]. Patients with low lean 
body mass may therefore be exposed to higher concentrations of cytotoxic drugs than those 
with higher lean body mass. Supporting this, a previous study of epirubicin 
pharmacokinetics demonstrated an association between epirubicin clearance and lean body 
mass [32]. 
 Our findings that sarcopenia is associated with decreased treatment tolerance may 
have important clinical implications. First, these results may guide supportive care 
measures in the DLBCL population. Current guidelines recommend use of primary G-CSF 
prophylaxis in patients with DLBCL >=65 years who are being treated with R-CHOP, 
although other considerations including comorbidities may be taken into account [16]. 
While this retrospective study must be confirmed by future studies, physicians could 
consider broader use of primary G-CSF prophylaxis in patients with sarcopenia who may 
not otherwise fulfill current criteria. Second, given that most treatment-related deaths 
occurred during the first cycle of chemotherapy, our findings may support the use of pre-
phase treatment in elderly patients with sarcopenia. Pre-phase treatment involves 
corticosteroids for 7 days prior to initiation of chemotherapy, and was used in the German 
High-Grade Non-Hodgkin’s Lymphoma Study Group (DSHNHL) trials in elderly patients 
[33,34]. A decrease in early treatment-related deaths and improvement in performance 
status was observed in elderly patients who underwent pre-phase treatment, although no 
statistical data was available to support this clinical experience [33]. Third, evaluation of 
sarcopenia could be used to guide treatment planning and dosing, particularly in the elderly. 
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While maintaining high dose-intensity improves overall survival, identification of elderly 
patients fit for full-dose therapy is challenging. A dose-reduced R-CHOP regimen (R-
miniCHOP) has been shown to be safe and effective in a cohort of patients with DLBCL 
greater than 80 years old [28]. Future prospective studies investigating the use of body 
composition parameters in guiding supportive care and treatment decisions are warranted.  
There are multiple strengths to this study. First, the VHA provided a large study 
cohort with comprehensive clinical data drawn from patients diagnosed and treated 
throughout the United States. Second, patients had an equal opportunity for inclusion 
regardless of comorbidities or other factors that may introduce selection bias observed in 
studies of patients enrolled in clinical trials.  
Limitations to this study should be noted. First, 70% of the study cohort did not 
have CT scans available for analysis, potentially introducing selection bias. To address 
these concerns, we compared baseline characteristics between those who did and did not 
have CT scans, and found no statistically significant differences. Second, the European 
Working Group on Sarcopenia in Older People released a consensus definition on 
sarcopenia, which recommends using the presence of both low muscle mass and low 
muscle function to diagnosis sarcopenia [35]. Because of the retrospective nature of our 
study, we were unable to measure muscle function. We were also unable to control for 
performance status, as this information was not available in many patients. Third, multiple 
threshold values used for defining sarcopenia exist in the literature. We chose to use the 
sex-specific threshold values reported by Martin et al. for overweight patients because it is 
the largest study of sarcopenia in cancer patients to date, and because 63% of our patients 
have a BMI of 25 or higher [23]. Fourth, the study cohort was comprised almost entirely of 
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men, which may limit our ability to extrapolate these findings to women. Finally, the VHA 
largely serves individuals who served in the United States military, who at the time of their 
service met the physical requirements for military enlistment. As a result, it is possible that 
the veteran population may be more physically fit and have higher muscle mass than 
average, potentially influencing the generalizability of our findings to the general 
population. 
 In conclusion, baseline sarcopenia was associated with poor treatment tolerance in 
patients with DLBCL undergoing CHOP-based chemotherapy. After controlling for other 
variables, baseline sarcopenia was independently associated with increased risk for febrile 
neutropenia hospitalizations and inability to complete the standard number of treatment 
cycles compared to no baseline sarcopenia. There was also a non-statistically significant 
trend towards increased treatment-related mortality in sarcopenic patients compared to non-
sarcopenic patients. Future prospective studies examining the utility of body composition 
parameters in guiding supportive care and treatment decisions in the DLBCL population are 
warranted. 
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Figure and Table Legends  
Figure 1: Example of CT muscle area assessment. (A) Example of abdominal CT image at 
the third lumbar vertebral level. (B) CT image is thresholded to -29 to 150 HU. CT 
numbers above this range are shown as white pixels and CT numbers below this range are 
shown as black pixels. (C) Thresholded CT image is copied into ImageJ and black and 
white values are removed, leaving only areas corresponding to skeletal muscle density. 
Skeletal muscle is manually selected and area is calculated in cm
2
. 
Abbreviations: CT=computed tomography; HU=Hounsfield unit 
Figure 2: STROBE Diagram 
Abbreviations: CNS=Central nervous system; OSH=outside hospital; CT=computed 
tomography; CHOP +/- R=cyclophosphamide, doxorubicin, vincristine, and prednisone, 
with or without rituximab; HIV=human immunodeficiency virus 
Table I: Demographic characteristics, dose characteristics, and toxicity outcomes of US 
veterans diagnosed with DLBCL from 1998 to 2008 according to sarcopenia status 
Footnotes: ‡ T test, * Chi-square test, § Mann-Whitney U-test 
Abbreviations: DLBCL=diffuse large B-cell lymphoma; US=United States; STD=standard 
deviation; IQR=interquartile range; LDH=lactate dehydrogenase; 
CHOP=cyclophosphamide, doxorubicin, vincristine, and prednisone, without rituximab; R-
CHOP=cyclophosphamide, doxorubicin, vincristine, and prednisone, with rituximab; 
BMI=body mass index; G-CSF=granulocyte-colony stimulating factor 
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Table II: Univariate and multivariable logistic regression analysis of factors associated 
with hospitalization for febrile neutropenia 
Abbreviations: OR=odds ratio; CI=confidence interval; LDH=lactate dehydrogenase; 
ARDI=average relative dose intensity; G-CSF=granulocyte-colony stimulating factor 
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Table I: Demographic characteristics, dose characteristics, and toxicity outcomes of US veterans 
diagnosed with DLBCL from 1998 to 2008 according to sarcopenia status 
 Clinical and 
demographic 
characteristics 
No sarcopenia n=277   Sarcopenia n=245   p value 
n %   n %     
Age (mean years, STD, 
IQR) 
61.2 (11.4, 15) -   68.1 (10.7, 17) -   <0.001‡ 





Race             0.005* 
White 232 83.8   228 93.1     
Black 42 15.2   16 6.5     
Other 3 1.1   1 0.4     
Comorbidity score 
(mean, STD, IQR) 
1.9 (1.9, 3.0) - 
 
2.3 (2.0, 3.0) - 
 
0.018‡ 
Stage             0.172* 
Stage I/II 116 41.9   94 38.4     
Stage III/IV 158 57.0   151 61.6     
Unknown 3 1.1   0 0.0     
LDH 
      
0.168* 












B-symptoms             0.004* 
Yes 129 52.7   147 60.0     
No 146 46.6   94 38.4     
Unknown 2 0.7   4 1.6     
Type of treatment 
      
0.618* 








Year of diagnosis 
(median) 
2005 -   2005 -   0.631§ 
BMI category at 
diagnosis (kg/m2)       
<0.001* 
















Number of cycles (mean, 
STD, IQR) 
5.4 (1.9, 2.0) -   4.9 (2.1, 2.5) -   0.007‡ 
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relative dose-intensity       
0.143* 




<85% 40 14.4 25 10.2 
Average relative dose-
intensity across all 
cycles             0.762* 
>=85% 166 59.9   150 61.2     
<85% 111 40.1   95 38.8     
Early G-CSF use 105 37.9 115 46.9 0.037* 
Hospitalization for 
febrile neutropenia 47 17.0   69 28.2   0.002* 
Treatment-related 
mortality 16 5.8 28 11.4 0.020* 
Footnotes: ‡ T test, * Chi-square test, § Mann-Whitney U-test  
Abbreviations: DLBCL=diffuse large B-cell lymphoma; US=United States; STD=standard 
deviation; IQR=interquartile range; LDH=lactate dehydrogenase; CHOP=cyclophosphamide, 
doxorubicin, vincristine, and prednisone, without rituximab; R-CHOP=cyclophosphamide, 
doxorubicin, vincristine, and prednisone, with rituximab; BMI=body mass index; G-
CSF=granulocyte-colony stimulating factor 
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Table II: Univariate and multivariable logistic regression analysis of factors associated with 
hospitalization for febrile neutropenia 
  
Univariate regression 
analysis   
Multivariable regression 
analysis 
  OR (95% CI) p   OR (95% CI) p 
Age >=65 years 1.82 (1.20 to 2.77) 0.005 
 
1.37 (0.85 to 2.20) 0.195 
Comorbidity score 1.22 (1.10 to 1.35) <0.001 
 
1.23 (1.09 to 1.39) <0.001 
Stage III/IV 1.63 (1.05 to 2.54) 0.03 
 
1.66 (1.04 to 2.65) 0.034 
B-symptoms, yes 1.71 (1.11 to 2.63) 0.014 
 
1.53 (0.97 to 2.44) 0.070 





2.21 (1.02 to 4.77) 0.044 
 
3.21 (1.40 to 7.40) 0.006 
Early G-CSF use 1.47 (0.97 to 2.23) 0.073 
 
- 
BMI     
   <18.5 4.36 (1.12 to 16.98) 0.033  2.89 (0.71 to 11.82) 0.138 
   18.5 to <25 Reference  Reference 
   >=25 0.96 (0.62 to 1.48) 0.853  1.23 (0.75 to 2.00) 0.415 
Baseline sarcopenia 1.92 (1.26 to 2.92) 0.002   1.64 (1.01 to 2.65) 0.046 
Abbreviations: OR=odds ratio; CI=confidence interval; LDH=lactate dehydrogenase; 
ARDI=average relative dose intensity; G-CSF=granulocyte-colony stimulating factor; 
BMI=body mass index 
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Figure 1: Example of CT muscle area assessment. (A) Example of abdominal CT image at the third lumbar 
vertebral level. (B) CT image is thresholded to -29 to 150 HU. CT numbers above this range are shown as 
white pixels and CT numbers below this range are shown as black pixels. (C) Thresholded CT image is 
copied into ImageJ and black and white values are removed, leaving only areas corresponding to skeletal 
muscle density. Skeletal muscle is manually selected and area is calculated in cm2.  
Abbreviations: CT=computed tomography; HU=Hounsfield unit  
171x53mm (300 x 300 DPI)  
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Figure 2: STROBE Diagram  
Abbreviations: CNS=Central nervous system; OSH=outside hospital; CT=computed tomography; CHOP +/- 
R=cyclophosphamide, doxorubicin, vincristine, and prednisone, with or without rituximab; HIV=human 
immunodeficiency virus  
88x98mm (300 x 300 DPI)  
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